Grail said it entered a securities purchase agreement expected to generate about $325 million in gross proceeds, a financing the company said will fund commercial activities and reimbursement work. The transaction covers the sale of 4,639,543 shares or pre‑funded warrants at $70.05 each and is expected to close Oct. 21. Institutional investors named in the deal include Deep Track Capital, Farallon and others. The company said the new funding, together with existing cash and a planned $110 million Samsung investment (subject to closing), will support operations into 2030. Grail’s Nasdaq stock jumped on the announcement, trading roughly 19% higher in morning trade. The raise sends a clear signal that Grail is prioritizing commercialization and reimbursement scale‑up for its cancer early‑detection business.